S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
NASDAQ:CSTL

Castle Biosciences - CSTL Stock Forecast, Price & News

$22.16
+0.60 (+2.78%)
(As of 03/23/2023 04:32 PM ET)
Add
Compare
Today's Range
$21.61
$22.64
50-Day Range
$19.47
$28.49
52-Week Range
$15.58
$47.27
Volume
135,290 shs
Average Volume
154,253 shs
Market Capitalization
$589.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.00

Castle Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
134.7% Upside
$52.00 Price Target
Short Interest
Healthy
3.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of Castle Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$597,542 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.96) to ($1.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

258th out of 986 stocks

Medical Laboratories Industry

10th out of 26 stocks


CSTL stock logo

About Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Receive CSTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CSTL Stock News Headlines

Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
SVB Securities Keeps Their Buy Rating on Castle Biosciences (CSTL)
Q4 2022 Castle Biosciences Inc Earnings Call
Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
Castle Biosciences
Pittsburgh lab receives pathology certification
See More Headlines
Receive CSTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CSTL Company Calendar

Last Earnings
11/07/2021
Today
3/23/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CSTL
Fax
N/A
Employees
342
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.00
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+133.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-67,140,000.00
Pretax Margin
-50.28%

Debt

Sales & Book Value

Annual Sales
$137.04 million
Book Value
$15.15 per share

Miscellaneous

Free Float
24,636,000
Market Cap
$591.14 million
Optionable
Not Optionable
Beta
1.05

Key Executives

  • Derek J. MaetzoldDerek J. Maetzold
    President, Chief Executive Officer & Director
  • Kristen M. OelschlagerKristen M. Oelschlager
    Chief Operating Officer
  • Franklin Michael Stokes
    Chief Financial Officer
  • Robert W. Cook
    Senior Vice President-Research & Development
  • Matthew Goldberg
    Medical Director













CSTL Stock - Frequently Asked Questions

Should I buy or sell Castle Biosciences stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CSTL shares.
View CSTL analyst ratings
or view top-rated stocks.

What is Castle Biosciences' stock price forecast for 2023?

6 Wall Street research analysts have issued 1 year price objectives for Castle Biosciences' shares. Their CSTL share price forecasts range from $38.00 to $80.00. On average, they anticipate the company's share price to reach $52.00 in the next year. This suggests a possible upside of 133.8% from the stock's current price.
View analysts price targets for CSTL
or view top-rated stocks among Wall Street analysts.

How have CSTL shares performed in 2023?

Castle Biosciences' stock was trading at $23.54 on January 1st, 2023. Since then, CSTL shares have decreased by 5.5% and is now trading at $22.24.
View the best growth stocks for 2023 here
.

Are investors shorting Castle Biosciences?

Castle Biosciences saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 862,000 shares, a drop of 25.0% from the February 13th total of 1,150,000 shares. Based on an average daily volume of 154,900 shares, the short-interest ratio is presently 5.6 days.
View Castle Biosciences' Short Interest
.

When is Castle Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our CSTL earnings forecast
.

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) posted its earnings results on Sunday, November, 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.13. The firm had revenue of $23.48 million for the quarter, compared to the consensus estimate of $23.66 million. Castle Biosciences had a negative trailing twelve-month return on equity of 15.45% and a negative net margin of 48.99%. During the same period last year, the firm posted ($0.23) earnings per share.

What guidance has Castle Biosciences issued on next quarter's earnings?

Castle Biosciences issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $170.00 million-$180.00 million, compared to the consensus revenue estimate of $168.34 million.

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

When did Castle Biosciences IPO?

(CSTL) raised $50 million in an IPO on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Castle Biosciences' stock symbol?

Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."

Who are Castle Biosciences' major shareholders?

Castle Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Granahan Investment Management LLC (3.96%), Millennium Management LLC (3.47%), Principal Financial Group Inc. (3.46%), Kornitzer Capital Management Inc. KS (2.72%), Portolan Capital Management LLC (2.22%) and Palisade Capital Management LLC NJ (2.09%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Bernhard E Spiess, Bonnie H Anderson, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Frank Stokes, Jeffrey E Eberwein, Joseph C Cook III, Kristen M Oelschlager, Mara G Aspinall, Sofinnova Healthquest Partners, Tiffany Olson and Tobin W Juvenal.
View institutional ownership trends
.

How do I buy shares of Castle Biosciences?

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Castle Biosciences' stock price today?

One share of CSTL stock can currently be purchased for approximately $22.24.

How much money does Castle Biosciences make?

Castle Biosciences (NASDAQ:CSTL) has a market capitalization of $591.14 million and generates $137.04 million in revenue each year. The company earns $-67,140,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis.

How many employees does Castle Biosciences have?

The company employs 342 workers across the globe.

How can I contact Castle Biosciences?

Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The official website for the company is castlebiosciences.com. The company can be reached via phone at (866) 788-9007 or via email at ir@castlebiosciences.com.

This page (NASDAQ:CSTL) was last updated on 3/23/2023 by MarketBeat.com Staff